Danske Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Danske Bank’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.5M	Buy	158,064 +5,058	+3%	+$2.24M	0.16%	114
2026 Q1	$68.3M	Sell	153,006 -4,159	-3%	-$1.94M	0.16%	118
2025 Q4	$71.3M	Sell	157,165 -7,315	-4%	-$3.15M	0.17%	112
2025 Q3	$64.4M	Sell	164,480 -42,266	-20%	-$17.7M	0.16%	115
2025 Q2	$92M	Buy	206,746 +46,956	+29%	+$21.6M	0.23%	79
2025 Q1	$77.5M	Sell	159,790 -2,513	-2%	-$1.17M	0.24%	79
2024 Q4	$65.4M	Sell	162,303 -16,124	-9%	-$7.47M	0.2%	87
2024 Q3	$83M	Sell	178,427 -25,046	-12%	-$12M	0.28%	61
2024 Q2	$95.4M	Sell	203,473 -31,021	-13%	-$13.5M	0.35%	43
2024 Q1	$98M	Buy	+234,494	New	+$99.1M	0.31%	62

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Danske Bank's VRTX Position: Q2 2026 in Review

Danske Bank increased its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q2 2026, buying an estimated $2.24M and bringing the position to 158,064 shares worth $78.5M. The position accounts for 0.16% of the portfolio, ranked #114.

Danske Bank first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $98M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Danske Bank held 158,064 shares of Vertex Pharmaceuticals worth $78.5M as of Q2 2026.
Danske Bank bought 5,058 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.24M.
Vertex Pharmaceuticals made up 0.16% of Danske Bank's portfolio in Q2 2026, its #114 holding.
Danske Bank first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Danske Bank's Vertex Pharmaceuticals position peaked at $98M in Q1 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.